Ponatinib, a next-generation TKI approved in imatinib-resistant BCR-ABL leukemia, has shown activity in engineered and GIST-derived cell lines, potently inhibitsKIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop, and has been shown to induce regression in engineered and GIST-derived tumor models containing these secondary mutations66. The gene discussed is ABL1; the disease is gastrointestinal stromal tumor.